GeneDx Holdings Corp. Class A Common Stock Q1 2026 Earnings Recap

Shares plunged 47.2% following GeneDx Holdings' earnings release, driven by a significant revenue shortfall mainly due to lower-than-expected reimbursement rates and underperformance in non-core businesses, prompting a downward revision of full-year guidance.

Key Takeaways

• Q1 test volume grew 34% year-over-year, indicating strong market demand and early growth in expansion markets.
• Total revenue missed expectations by $12 million, attributed to a $5.5 million shortfall from lower blended average reimbursement rates and a $6.5 million shortfall in non-core businesses.
• Full-year revenue guidance was lowered to a range of $475 million to $490 million, reflecting ongoing challenges in reimbursement and softer contributions from Fabric and biopharma segments.
• Gross margins are expected to hold near 70%, with commitments to return to adjusted profitability in 2026 and significant profitability growth anticipated in 2027.
• The company is focusing resources on core diagnostic offerings and international expansion of the Fabric business, while biopharma sales cycles remain elongated, delaying expected revenue ramp.